Oral Factor Xa Inhibitors Market to Climb $41.24 Bn by 2034

Oral Factor Xa Inhibitors Market Companies, Segmental Analysis and Growth

The global oral factor Xa inhibitors market was estimated at US$ 21.5 billion in 2023 and is projected to grow to US$ 41.24 billion by 2034, rising at a compound annual growth rate (CAGR) of 6.1% from 2024 to 2034. The demand for oral factor Xa inhibitors is increasing due to their ease of use. The inhibitors are easy to store and consume and do not require any professionals to administer them.

Unlock Infinite Advantages: Subscribe to Annual Membership

Market Overview

The oral factor Xa inhibitors market deals with the development and production of various drugs used as anticoagulants. These anticoagulants inhibit Xa factors that prevent blood clotting. Some of the examples of anticoagulants that inhibits Xa factor are apixaban, rivaroxaban, and edoxaban. Oral inhibitors are consumed in the form of tablets or capsules and do not require professionals to administer them, which gives them an advantage over injectables. The demand for these inhibitors is high in the market due to the growing prevalence of various cardiovascular diseases. Cardiovascular disease remains the leading cause of death worldwide. Using anticoagulants helps in preventing emergency or life-threatening situations.

Oral Factor Xa Inhibitors Market Trends

• In May 2023, In order to meet the World Health Organization's goal of a 25% reduction in premature deaths from noncommunicable illnesses by 2025, efforts must focus on cardiovascular disease with the help of direct oral anticoagulants.
• Since January 2022, more than 460,000 more people have begun taking anticoagulant medications, and more than 24 million prescriptions have been written for patients, averting an estimated 17,000 strokes and 4,000 fatalities. One in five strokes is caused by atrial fibrillation (AF), which affects around 1.5 million individuals in England.
• In January 2022, NHS commissioning guidelines suggested edoxaban as a preferred choice for prescribers since it was the most cost-effective of the four approved DOACs. This recommendation saved the NHS more than £100 million in medical expenses.

The Growing Cases of Strokes Demand for Anticoagulants

Worldwide, more than 100 million people have had a stroke. More than 60% of strokes occur in adults under 70, and 16% occur in those under 50. By 2030, the entire cost of stroke is predicted to reach US$1 trillion US$, and its economic effect now accounts for 0.66% of the world's GDP. These individuals' risk of ischemic stroke is decreased when the right anticoagulants are used. Finding the optimum antiplatelet and anticoagulant combination in a safe and effective preventative guideline is a major medical objective. Oral direct factor Xa inhibitors have been approved by the U.S. FDA to prevent stroke.

High-Cost Restraint the Oral Factor Xa Inhibitors Market

US$3,784.20 was the cost per patient for a 28-day treatment of factor Xa inhibitor. Factor Xa inhibitors for a 28-day course of treatment, including follow-up and per-patient fees, totaling US$77,125.60 dollars. US$4,370.93 was the weighted average cost per patient for a 28-day treatment. In the United States, the yearly cost differential may reach more than US$14.1 billion by 2040. Factor Xa inhibitor thromboprophylaxis can cost up to 1,980.6% more per patiens than an aspirin regimen because of greater main treatment costs, variable PJI rates, and high management expenses.

Regional Insights

North America dominated the oral factor Xa inhibitors market in 2023.

The North American market is growing strongly due to many factors. These factors include investments in research & development, advanced infrastructure, innovation & growth in the pharmaceutical industry, growing cases of cardiovascular diseases, and government support. Various countries contribute to the growth, among which the U.S. and Canada are the major contributors. These countries have advanced technology, highly skilled professionals, and all the resources needed by key market players and organizations to conduct research, clinical trials, and experiments. This boosts the region, and the organizations are able to invest in other regions as well.

The U.S. held the major share of the oral factor Xa inhibitors market mainly due to resources, a dominant pharmaceutical industry, and the presence of major market players. Another factor that contributed to the market’s growth is the growing prevalence of cardiovascular disease. It is a leading cause of death, and stakeholders are continuously making efforts to mitigate the burden of cardiovascular diseases on the healthcare system.

For instance,

• For men, women, and members of the majority of racial and ethnic groups, heart disease is the top cause of mortality in the U.S., according to the CDC. 702,880 persons lost their lives to heart disease in 2022. That is the same as one death out of every five. Approximately 805,000 Americans have a heart attack each year. Of them, 200,000 are people who have already experienced a heart attack, and 605,000 are those who are having their first heart attack.

Asia Pacific is expected to grow at the fastest rate during the forecast period.

The oral factor Xa inhibitors market is growing significantly due to the growing geriatric population. This group of people is prone to various cardiovascular diseases due to age-related decline in health. Apart from this, various organizations are investing in Asia Pacific’s market due to growing potential in healthcare and pharmaceuticals. Countries like India, China, South Korea, and Japan holds majority of share out of which China is dominant and India is emerging as a potential market place.

There are thought to be 330 million CVD patients in China at the moment. Without health care reform, health spending will rise from USD 543.5 billion in 2014 to USD 2.5 trillion in 2035, according to a joint analysis by the World Bank and the Chinese government. In order to address the issue of growing healthcare expenditures, the Chinese government has initiated significant reforms and implemented significant structural changes. The Chinese government's health and development program places a strong emphasis on creating a "Healthy China," which might have enormous positive effects on the rest of the globe. In the last twenty years, more than ninety-five percent of Chinese people now have health insurance. Due to economic development and increased personal earnings, the nation has been able to raise 600 million people out of poverty during the past three decades.

Segmental Insights

By type, the apixaban segment held a significant share of the oral factor Xa inhibitors market in 2023. Apixaban is an oral bioavailable, strong, and highly selective inhibitor. Apixaban is well tolerated and safe; neither the single ascending dosage nor the food impact trial showed any significant bleeding-related events or serious adverse events.

The rivaroxaban segment is estimated to grow at a significant rate during the forecast period. One new oral anticoagulant (NOAC) medication is rivaroxaban. It has a number of off-label and FDA-approved clinical applications. Rivaroxaban is quickly absorbed, peaking in concentration in 2–4 hours, and has a high oral bioavailability (80%).

By application, the atrial fibrillation segment held a significant share of the oral factor Xa inhibitors market in 2023 and is expected to grow significantly during the predicted period. As the number of patients with atrial fibrillation (AF) keeps rising, it is imperative to avoid strokes in this disease safely and effectively. For this indication, a number of innovative oral anticoagulants are being explored to replace warfarin. Since factor Xa inhibition is known to be a viable target for therapeutic anticoagulation, direct factor Xa inhibitors make up the biggest class of oral anticoagulants now under research.

Recent Developments

• In August 2024, the "maximum fair price" (MFP) for ELIQUIS® (apixaban), which was chosen during the first round of government price setting under the Inflation Reduction Act (IRA), was announced by the U.S. Department of Health and Human Services, according to Pfizer Inc. As of January 1, 2026, Medicare will cover $231.00 for a 30-day equivalent supply of ELIQUIS, the medication's necessary MFP.
• In February 2024, in countries where the CE mark is recognized, Roche announced the introduction of three new coagulation tests for the oral Factor Xa inhibitors: rivaroxaban, edoxaban, and apixaban.

Top Companies in the Oral Factor Xa Inhibitors Market

• Hansoh Pharma
• Pfizer
• Kelun Pharmaceutical
• Zhejiang Hisun Pharmaceutical
• BrightGene
• GlaxoSmithKline
• Accord Healthcare
• Qilu Pharmaceutical
• Dr. Reddy's Laboratories
• Chia Tai Tianqing Pharmaceutical
• Lupin
• HEC Pharma
• Cspc Ouyi Pharmaceutical
• Nanjing King-Friend Biochemical Pharmaceutical
• Jiangsu Hengrui Pharmaceuticals
• Bristol Myers Squibb
• Eugia Pharma
• Apotex
• Viatris
• Janssen Pharmaceuticals
• Shanghai Huilun Pharmaceutical
• Bayer
• Daiichi Sankyo
• Zydus

Segments Covered in the Report

By Type

• Rivaroxaban
• Edoxaban
• Apixaban

By Application

• Atrial Fibrillation
• Deep Vein Thrombosis
• Pulmonary Embolism
• Other

By Region

• North America
  • U.S.
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait